Cargando…
Inhibiting DosRST as a new approach to tuberculosis therapy
Progress against tuberculosis (TB) requires faster-acting drugs. Mycobacterium tuberculosis (Mtb) is the leading cause of death by an infectious disease and its treatment is challenging and lengthy. Mtb is remarkably successful, in part, due to its ability to become dormant in response to host immun...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Newlands Press Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607383/ https://www.ncbi.nlm.nih.gov/pubmed/32053005 http://dx.doi.org/10.4155/fmc-2019-0263 |